Corza's take on the Life Science sector post COVID-19

Corza's take on the Life Science sector post COVID-19

Corza Health is a consulting company providing assistance to healthcare and life sciences companies in order to achieve a market-leader position. Its operational agenda involves versatile, unique strategies to accelerate growth and expand the equity value of the companies.


How does Corza distinguish itself from its competitors?

Corza Health is a globally oriented Life Sciences company that seeks to build innovative and transformative operating companies. We distinguish ourselves by leveraging our domain expertise, our global operating experiences, and our ability to invest significant amounts of capital in accelerating growth and profitability.   Our team consists of executives that have a diversified set of experiences to include leading public and private companies, building global operating companies through Mergers & Acquisitions, and developing transformative technologies through product development and innovation.      


Please help us understand the changes in the company’s business line due to the Coronavirus outbreak in 2020.

Coronavirus has minimally impacted our business activities and investing efforts.  We experienced a slight delay with various projects that we were pursuing through the end of May.  During the month of June, we experienced an increase in business activity that has persisted into August.  We are quite optimistic about the balance of the year, 2021, and 2022.   Some market segments within the Life Sciences have been more severely impacted than others, such as Ophthalmology and Dental, and will require more time to recover.  As we consider investing capital, we are evaluating the health and recovery attributes of the various industry segments to identify opportunities that will experience sustainable growth for several years. 


What are the opportunities that you see in the near future?

Healthcare and the Life Science markets continue to experience persistent demand, which is driven by the prevalence and incidence of disease around the world.  Underlying diseases continue to create opportunities for various therapies in the form of new innovative medical devices or advanced pharmaceutical drugs. Innovation such as, robotic surgery has demonstrated improvement in patient outcomes and cost-efficiency, situations where patients are recovering quicker, and hospitals are delivering quality care at a reduced cost. 

At Corza Health, we are focused on building innovative and transformative global operating companies. So we see many opportunities to build better performing global companies that will more efficiently serve our healthcare provider customers, ultimately benefiting patients around the world.  As an example, we are good at pairing geographically dispersed companies together in the US, Europe, and Asia to create a more cohesive and globally-minded organization.  This positions us more effectively to leverage better technology, best practices, human capital in providing innovative devices and products to our global patients.       


How is the company planning to leverage its products or services amidst the pandemic situation?

As I mentioned earlier, the Coronavirus minimally impacted our business activities and investing efforts.  However, it has impacted the financial performance of many companies around the world.  As these companies plan for recovery, I believe that our capabilities at Corza Health are now more valuable than ever. As an example, we can leverage our operating experience and expertise in building high performing commercial organizations to reinvigorate sales growth. Moreover, we can help implement an efficient reorganization to maintain a company’s competitiveness ensuring financial strength and market positioning to grow market share as demand in the market returns.   


What is the strategic advantage gained by the merger of GTCR and Gregory T Lucier?

The strategic advantages include Capital, Global Operating Experience, Strategy and Deal Execution.  GTCR is one of the most successful and well-respected investment firms in North America, and Greg Lucier is one of the most well-respected public operating executives in the region. Combining these two results is extremely enticing to executives and corporate partners who have an interest in accelerating the growth of their company. We seek to align ourselves and partner with those companies that have a strong desire to continue to build a more innovative and transformative enterprise. 


Are there any plans to expand your business to other geographic locations?

We are globally minded, globally focused, and are searching for opportunities around the world. In almost every corner of the globe are opportunities to better serve healthcare providers and patients.  The rate of growth and demand vary throughout the regions around the world. So for our areas of focus, we are exploring specific regions that align well with our capabilities. 


What are the opportunity areas that you see in 2021?

The specific areas that are of interest to us include the Life Science Tools, Medical Devices, and Medical Device Contract Manufacturing. Both the short term and long term outlook for these segments are positive and are supported by the growth of the underlying disease adversely affecting patients around the world.